Valuation: LadRx Corporation

Market Cap 5.45K 4.74K 4.49K 4.08K 7.62K 522K 7.66K 53.47K 20.68K 265K 20.46K 20K 849K P/E 2023
1.91x
P/E 2024 -0.52x
Enterprise Value -754K -657K -622K -565K -1.06M -72.24M -1.06M -7.41M -2.86M -36.71M -2.83M -2.77M -118M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
1 day-99.09%
1 week+400.00%
Current month-90.91%
1 month-90.91%
3 months-99.07%
6 months-98.04%
Current year-90.91%
1 week 0
Extreme 0.0002
0.02
1 month 0
Extreme 0.0002
0.02
Current year 0
Extreme 0.0002
0.11
1 year 0
Extreme 0.0001
1.33
3 years 0
Extreme 0.0001
3.5
5 years 0
Extreme 0.0001
86
10 years 0
Extreme 0.0001
598.8
Date Insider Type Main position Quantity % Market Cap. Importance
15/01/24 Free

Director

5,000 1.0099%
15/01/24 Free

Chairman

5,000 1.0099%
15/01/24 Free

Director

5,000 1.0099%
Change 5-day change 1-year change 3-year change Capi.($)
-99.09%+400.00%-99.93%-99.93% 5.45K
+1.23%+1.87%-0.15%+28.45% 45.91B
+0.54%+5.06%+44.80%+29.13% 44.25B
-0.06%-4.14%+344.94%+530.23% 41.99B
+1.54%+3.35%+6.34%+69.10% 39.58B
+1.75%-1.53%+12.22%+41.11% 31.08B
+0.64%+6.28%+24.49%+126.93% 17.21B
-3.44%-8.73% - - 16.27B
+2.92%+8.40%+22.46%+39.73% 14.96B
-2.14%+3.01%-2.59%-35.11% 13.42B
Average -9.60%+1.38%+39.18%+81.07% 26.47B
Weighted average by Cap. +0.63%+0.68%+71.72%+125.53%

Financials

2023 2024
Net sales - -
Net income 400K 349K 330K 300K 560K 38.35M 563K 3.93M 1.52M 19.49M 1.5M 1.47M 62.39M -1.59M -1.38M -1.31M -1.19M -2.22M -152M -2.24M -15.61M -6.04M -77.37M -5.97M -5.84M -248M
Net Debt -2.04M -1.77M -1.68M -1.53M -2.85M -195M -2.86M -20M -7.73M -99.12M -7.65M -7.48M -317M -760K -662K -626K -569K -1.06M -72.76M -1.07M -7.46M -2.88M -36.98M -2.85M -2.79M -118M
Logo LadRx Corporation
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
Employees
2
Date Price Change Volume
16/09/26 US$0.0110 +5,400.00% 715
11/09/26 US$0.000200 -.--% 527
  1. Stock Market
  2. Stocks
  3. LADX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!